
SGLT-2 Inhibitors Decrease Risk of Serious Liver Events
The use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors were associated with a decreased risk of serious liver events among patients with cirrhosis, according to data published in JAMA Network Open.1 “[SGLT-2] inhibitors are a class of …